1.61
+0.095(+6.27%)
Currency In USD
Address
5959 Horton Street
Emeryville, 94608
United States of America
Phone
510-871-4880
Website
Sector
Healthcare
Industry
Biotechnology
Employees
202
First IPO Date
April 06, 2006
| Name | Title | Pay | Year Born |
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, Chief Executive Officer & Chairman of the Board | 913,299 | 1969 |
| Ms. Pamela M. Wapnick M.B.A. | Chief Financial Officer | 581,813 | 1966 |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer | 591,494 | 1968 |
| Dr. Jian Irish M.B.A., Ph.D. | President, Chief Operating Officer & Director | 734,626 | 1964 |
| Dr. Alan Brooks Ph.D. | Head of Preclinical | 0 | 1966 |
| Dr. Joseph Knowles M.D. | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Dr. Christopher Brown | Head of Discovery | 0 | 1989 |
| Mr. Matthew L. Wein J.D. | Senior Vice President, Head of Legal, Compliance Officer & Corporate Secretary | 0 | 1971 |
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.